Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DENISE A YARDLEY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1801829114
CMS profile
36050
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$12,075.16

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,245.60 4
Food and Beverage $2,301.54 85
Long term medical supply or device loan $1,147.29 12
Travel and Lodging $380.73 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DENISE A YARDLEY

NPI 1801829114 · CMS profile ID 36050

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DENISE A YARDLEY, NPI 1801829114, CMS profile ID 36050. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DENISE A YARDLEY, NPI 1801829114, CMS profile ID 36050. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DENISE A YARDLEY, NPI 1801829114, CMS profile ID 36050, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1801829114?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $12,075.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–102 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PharmaEssentia USA Corporation $18.2001/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246831637 CMS
AstraZeneca Pharmaceuticals LP $18.5701/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214786539 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,853.61 83
PY2020 $8,855.84 19
PY2021 $6,352.93 7
PY2022 $15,706.77 22
PY2023 $13,837.89 43
PY2024 $32,159.11 96
PY2025 $12,075.16 102

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,578.94 2
PY2025 Principal investigator $809,805.84 143
PY2024 Recipient $8,186.87 1
PY2024 Principal investigator $335,282.66 58
PY2023 Recipient $16,456.43 6
PY2023 Principal investigator $1,184,465.63 66
PY2022 Recipient $952.00 2
PY2022 Principal investigator $2,109,619.40 67
PY2021 Recipient $27,760.00 3
PY2021 Principal investigator $3,398,665.70 75
PY2020 Recipient $6,422.00 6
PY2020 Principal investigator $4,199,414.73 184
PY2019 Recipient $25,205.79 5
PY2019 Principal investigator $1,092,374.62 226

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

145 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $3,402.83 12/31/2025 Non-covered Recipient Entity
Tennessee Oncology, PLLC,The Sarah Cannon Research Institute
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232927163
Principal investigator 1 Genentech, Inc. $3,049.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211650039
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/18/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767795
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/18/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767797
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/15/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767823
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/15/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767825
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/10/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767817
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/10/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767819
Principal investigator 1 Genentech, Inc. $2,695.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211650036
Principal investigator 1 Genentech, Inc. $42.00 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211650002
Principal investigator 1 Boehringer Ingelheim International GmbH $4,644.00 12/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767799
Principal investigator 1 Boehringer Ingelheim International GmbH $8,296.00 12/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767801
Principal investigator 1 Boehringer Ingelheim International GmbH $1,774.00 12/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767803
Principal investigator 1 Boehringer Ingelheim International GmbH $3,474.00 12/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767805
Principal investigator 1 Boehringer Ingelheim International GmbH $705.00 12/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767807
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767791
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767793
Principal investigator 1 Boehringer Ingelheim International GmbH $5,775.00 12/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767809
Principal investigator 1 Boehringer Ingelheim International GmbH $4,000.00 12/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767811
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767813
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 12/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767815
Principal investigator 1 Boehringer Ingelheim International GmbH $5,200.00 12/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767821
Principal investigator 1 Genentech, Inc. $2,500.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211652705
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 11/20/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767787
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 11/20/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767789
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,500.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185541750
Principal investigator 1 GlaxoSmithKline, LLC. $5,200.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192156907
Principal investigator 1 GlaxoSmithKline, LLC. $19,500.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192156913
Principal investigator 1 GlaxoSmithKline, LLC. $2,900.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192156921
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192185265
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192185278
Principal investigator 1 GlaxoSmithKline, LLC. $2,900.00 11/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192185282
Principal investigator 1 GlaxoSmithKline, LLC. $4,151.25 11/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192185286
Principal investigator 1 Boehringer Ingelheim International GmbH $4,915.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767761
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767763
Principal investigator 1 Boehringer Ingelheim International GmbH $1,986.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767765
Principal investigator 1 Boehringer Ingelheim International GmbH $5,231.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767767
Principal investigator 1 Boehringer Ingelheim International GmbH $355.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767769
Principal investigator 1 Boehringer Ingelheim International GmbH $3,617.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767771
Principal investigator 1 Boehringer Ingelheim International GmbH $705.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767773
Principal investigator 1 Boehringer Ingelheim International GmbH $705.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767775
Principal investigator 1 Boehringer Ingelheim International GmbH $705.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767777
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767779
Principal investigator 1 Boehringer Ingelheim International GmbH $371.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767781
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767783
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 11/03/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767785
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767757
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767759
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81,860.85 10/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220998295
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $122,791.28 10/31/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220998297
Principal investigator 1 GlaxoSmithKline, LLC. $17,749.80 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192156903
Principal investigator 1 GlaxoSmithKline, LLC. $3,930.53 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192156918
Principal investigator 1 PFIZER INC. $3,000.00 10/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228741772
Principal investigator 1 GlaxoSmithKline, LLC. $5,800.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192185269
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 10/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC No dispute reported 06/30/2026 1192185274
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/22/2025 Non-covered Recipient Entity
Scri Oncology Partners
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175273191
Principal investigator 1 PFIZER INC. $3,000.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228730585
Principal investigator 1 PFIZER INC. $3,000.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228730607
Principal investigator 1 PFIZER INC. $169.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228741731
Principal investigator 1 Genentech, Inc. $2,500.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211652384
Principal investigator 1 Genentech, Inc. $9,713.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211652421
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,064.05 10/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190309512
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767753
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767755
Principal investigator 1 Genentech, Inc. $2,500.00 09/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211652311
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,645.54 09/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190303751
Principal investigator 1 Genentech, Inc. $2,500.00 09/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651975
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767745
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767747
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,089.13 08/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185541748
Principal investigator 1 Genentech, Inc. $2,500.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211649841
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767741
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767743
Principal investigator 1 PFIZER INC. $3,000.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228762362
Recipient Novartis Pharmaceuticals Corporation $3,395.14 07/17/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190292445
Principal investigator 1 Genentech, Inc. $10,178.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211652193
Principal investigator 1 Genentech, Inc. $2,500.00 07/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651926
Principal investigator 1 Genentech, Inc. $3,067.75 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211649874
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767749
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767751
Principal investigator 1 Novartis Pharmaceuticals Corporation $526.84 07/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190303749
Principal investigator 1 PFIZER INC. $1,630.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228778200
Principal investigator 1 PFIZER INC. $1,479.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228786747
Principal investigator 1 PFIZER INC. $5,200.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228791945
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 06/24/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767727
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767729
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 06/24/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767731
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 06/24/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767733
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 06/24/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767735
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 06/24/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767737
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 06/24/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767739
Principal investigator 1 PFIZER INC. $3,000.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228792884
Principal investigator 1 PFIZER INC. $3,000.00 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228793190
Principal investigator 1 Genentech, Inc. $2,500.00 06/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211650899
Principal investigator 1 Novartis Pharmaceuticals Corporation $85,176.46 06/17/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190310168
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767723
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767725
Principal investigator 1 Genentech, Inc. $1,056.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651516
Principal investigator 1 Genentech, Inc. $2,500.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651563
Principal investigator 1 Merck Sharp & Dohme LLC $3,150.00 05/28/2025 Non-covered Recipient Entity
Tennessee Oncology, PLLC,The Sarah Cannon Research Institute
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232927119
Principal investigator 1 PFIZER INC. $588.00 05/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228773590
Recipient Novartis Pharmaceuticals Corporation $1,183.80 05/13/2025 Covered Recipient Physician CLEE011O12301C No dispute reported 06/30/2026 1190292441
Principal investigator 1 PFIZER INC. $43,996.68 05/13/2025 Non-covered Recipient Entity
Tennessee OncologyNashvilleSarah Cannon Research Institute
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228754976
Principal investigator 1 PFIZER INC. $10,940.00 05/13/2025 Non-covered Recipient Entity
Tennessee OncologyNashvilleSarah Cannon Research Institute
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228758068
Principal investigator 1 PFIZER INC. $43,996.68 05/12/2025 Non-covered Recipient Entity
Tennessee OncologyNashvilleSarah Cannon Research Institute
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228757695
Principal investigator 1 PFIZER INC. $10,940.00 05/12/2025 Non-covered Recipient Entity
Tennessee OncologyNashvilleSarah Cannon Research Institute
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228758028
Principal investigator 1 PFIZER INC. $3,000.00 05/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228782356
Principal investigator 1 PFIZER INC. $3,000.00 05/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228782461
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767719
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767721
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 04/25/2025 Non-covered Recipient Entity
Scri Oncology Partners
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175274309
Principal investigator 1 Genentech, Inc. $8,682.00 04/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651127
Principal investigator 1 Genentech, Inc. $2,500.00 04/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651077
Principal investigator 1 Genentech, Inc. $2,500.00 04/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651045
Principal investigator 1 Genentech, Inc. $2,500.00 04/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211651190
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767715
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767717
Principal investigator 1 Novartis Pharmaceuticals Corporation $600.00 03/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
SOLAR1 A phase III randomized double blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer which progressed on or after aromatase in No dispute reported 06/30/2026 1190304449
Principal investigator 1 PFIZER INC. $3,000.00 03/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228783757
Principal investigator 1 Genentech, Inc. $2,500.00 03/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211650352
Principal investigator 1 Genentech, Inc. $2,500.00 03/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211650502
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 03/07/2025 Non-covered Recipient Entity
Scri Oncology Partners
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175274496
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767699
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767701
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 02/26/2025 Non-covered Recipient Entity
Scri Oncology Partners
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175274528
Principal investigator 1 Boehringer Ingelheim International GmbH $475.16 02/25/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767703
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 02/25/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767705
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 02/25/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767707
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 02/25/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767709
Principal investigator 1 Boehringer Ingelheim International GmbH $82.00 02/25/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767711
Principal investigator 1 Boehringer Ingelheim International GmbH $32.12 02/25/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767713
Principal investigator 1 Janssen Research & Development, LLC $252.90 02/12/2025 Non-covered Recipient Entity
Scri Oncology Partners
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175273353
Principal investigator 1 PFIZER INC. $3,000.00 02/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228796219
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767695
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767697
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 01/30/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767689
Principal investigator 1 Genentech, Inc. $6,346.00 01/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211650634
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,250.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3- No dispute reported 06/30/2026 1190304457
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/14/2025 Non-covered Recipient Entity
Scri Oncology Partners
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175274146
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 01/13/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767687
Principal investigator 1 Novartis Pharmaceuticals Corporation $48,841.75 01/09/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGYPLLC SARAH CANNON CANCER CTR
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190310170
Principal investigator 1 PFIZER INC. $3,000.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228799043
Principal investigator 1 PFIZER INC. $3,000.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228801265
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767691
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Scri Oncology Partners
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220767693